
|Articles|August 23, 2012
Ethics and Oncology Medworm Feed
Advertisement
Powered by
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer
2
CAR T-Cell Expansion Predicts Toxicity, But Not Always Efficacy
3
Mapping the Full CAR T-Cell Journey in DLBCL From Referral to Survivorship
4
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
5


!["I can’t make [treatment] decisions for you, but I can give you realistic expectations," said Herbert Lepor, MD, of NYU Langone Health.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/11e93c561a9ff98f731b152d7f48e6f792831864-1000x1000.jpg?w=350&fit=crop&auto=format)


















































